Search Within

Owen O'connor

Formats
  1. Meeting Abstract (55)
  2. Journal Article (42)
  3. Book Section (1)
Groups
  1. Department of Medicine (57)
  2. Hematologic Malignancies, Division of (48)
  3. Center for Hematologic Malignancies (45)
  4. Lymphoma (42)
  5. Nursing (23)
  6. Population Sciences Research Program (21)

More Groups

People
  1. Andrew Zelenetz (39)
  2. Craig Moskowitz (35)
  3. David Straus (30)
  4. Carol Portlock (28)
  5. Paul Hamlin (23)
  6. Ariela Noy (22)

More People

Years
  1. 2010 (2)
  2. 2009 (2)
  3. 2008 (3)
  4. 2007 (8)
  5. 2006 (19)
  6. 2005 (17)

More Years

Publications
  1. Blood (30)
  2. Journal of Clinical Oncology (18)
  3. British Journal of Haematology (7)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (5)
  5. Clinical Cancer Research (4)
  6. Leukemia and Lymphoma (4)

More Publications

Publishers
  1. American Society of Hematology (30)
  2. American Society of Clinical Oncology (18)
  3. American Association for Cancer Research (11)
  4. John Wiley & Sons (7)
  5. Taylor & Francis Group (5)
  6. Springer (4)

More Publishers

Results (98)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The emerging role of Bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas
    Journal Article

    O'Connor, O. A.
    Current Treatment Options in Oncology (2004)

    Fulltext@MSK | Save
  • Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease
    Journal Article

    Portlock, C. S.; Donnelly, G. B.; Qin, J.; Straus, D.; Yahalom, J.; Zelenetz, A.; Noy, A.; O'connor, O.; Horwitz, S.; Moskowitz, C.; more...
    British Journal of Haematology (2004)

    Fulltext@MSK | Save
  • Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
    Journal Article

    Kewalramani, T.; Zelenetz, A. D.; Nimer, S. D.; Portlock, C.; Straus, D.; Noy, A.; O'connor, O.; Filippa, D. A.; Teruya-Feldstein, J.; Gencarelli, A.; more...
    Blood (2004)

    Fulltext@MSK | Save
  • Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II
    Journal Article

    O'connor, O.; Wright, J.; Moskowitz, C. H.; Muzzy, J.; Macgregor-Cortelli, B.; Hamlin, P.; Straus, D.; Trehu, E.; Schenkein, D. P.; Zelenetz, A. D.
    Journal of the National Comprehensive Cancer Network (2004)

    Fulltext@MSK | Save
  • Phase II clinical experience with the novel proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent and mantle cell lymphomas
    Meeting Abstract

    O'Connor, O. A.; Wright, J.; Moskowitz, C.; Straus, D.; Macgregor-Cortelli, B.; Muzzy, J.; Choi, P.; Schenkein, D.; Zelenetz, A. D.
    EJC Supplements (2003)

    Fulltext@MSK | Save
  • Stanford V and radiotherapy for advanced and locally extensive Hodgkin's disease (HD): The memorial Sloan-Kettering Cancer Center (MSKCQ) experience
    Meeting Abstract

    Yahalom, J.; Edwards-Bennett, S.; Jacobs, J.; Moskowitz, C. H.; Wu, E. J.; Cotler, M.; Horwitz, S. M.; Noy, A.; O'Connor, O. A.; Portlock, C. S.; more...
    Blood (2003)

    Fulltext@MSK | Save
  • A novel antifolate 10-propargyl-10-deazaaminopterin (PDX) displays synergistic effects with gemcitabine in non-Hodgkin's lymphoma models in vitro and in vivo
    Meeting Abstract

    Vrhovac, R.; Toner, L. E.; Smith, E. A.; O'Connor, O. A.
    Blood (2003)

    Fulltext@MSK | Save
  • Promising activity of the proteasome inhibitor bortezomib (velcade) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    Meeting Abstract

    O'connor, O.; Wright, J.; Moskowitz, C. H.; Muzzy, J.; Macgregor-Cortelli, B.; Hamlin, P.; Straus, D.; Trehu, E.; Schenkein, D. P.; Zelenetz, A. D.
    Blood (2003)

    Fulltext@MSK | Save
  • Oblimersen (Bcl-2 antisense) enhances the antitumor activity of bortezomib (Bor) in multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) preclinical models
    Meeting Abstract

    O'connor, O.; Srinivasan, S.; Hernandez, F.; Smith, E. A.; Toner, L. E.; Czuczman, M. S.; Chanan-Khan, A. A.
    Blood (2003)

    Fulltext@MSK | Save
  • Risk-adpated high dose chemoradiotherapy and ASCT for patients with relapsed and primary refractory Hodgkin's disease: An intent to treat analysis
    Meeting Abstract

    Moskowitz, C. H.; Kewalramani, T.; Nimer, S. D.; Rice, R. D.; Rosenzweig, L.; Horwitz, S.; Noy, A.; O'connor, O.; Portlock, C. S.; Straus, D.; more...
    Blood (2003)

    Fulltext@MSK | Save